A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

Trial Profile

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs SNS 062 (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 According to a Sunesis Pharmaceuticals media release, the first patient has been dosed in this trial.
    • 08 May 2017 Status changed from not yet recruiting to recruiting.
    • 01 May 2017 According to a Sunesis media release, the compnay expects to begin dosing in this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top